Fresenius SE & Co. KGaA (VIE:FRE)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.51B +13.6% |
| Revenue (ttm) | 23.28B +3.4% |
| Net Income | 1.52B +35.3% |
| EPS | 2.70 +35.3% |
| Shares Out | n/a |
| PE Ratio | 17.42 |
| Forward PE | 12.35 |
| Dividend | 1.05 (2.36%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 762 |
| Open | 46.75 |
| Previous Close | 46.99 |
| Day's Range | 46.72 - 47.46 |
| 52-Week Range | 35.24 - 52.76 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
Fresenius Announces Climb In Q2 Bottom Line
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK) reported a profit for its second quarter that Increases, from the same period last yearThe company's earnings totaled EUR382 million, or ...
Fresenius SE & Co. KGaA Earnings Call Transcript: Q2 2026
Strong Q2 results featured double-digit EPS and EBIT growth, margin expansion, and robust cash flow, prompting an upgrade in full-year EPS guidance to 10%-15%. Growth was broad-based across Biopharma, MedTech, and Helios, with continued operational momentum and strategic flexibility.
Fresenius SE & Co. KGaA Slides: Q2 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Fresenius SE & Co. KGaA Earnings release: Q2 2026
Fresenius SE & Co. KGaA released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q2 2026
Fresenius SE & Co. KGaA has published its Q2 2026 quarterly earnings report on August 5, 2026.
Fresenius Raises 2026 Earnings Guidance on Strong Performance
Fresenius accelerates its growth trajectory, lifting 2026 earnings guidance as robust Q2 results, rising margins and solid segment performance underscore its strategic momentum.
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast / Full year Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performa...
Fresenius Kabi: Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan (rituximab) Rituximab is a CD20-directed cytolytic antibody used across multip...
Fresenius Kabi: Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intravenous vedolizumab biosimilar candidate, an integ...
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
BAD HOMBURG, Germany, July 23, 2026 /PRNewswire/ -- The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its ...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Fresenius Backs Annual Adj. Earnings Growth Outlook
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius (FSNPF.PK, FSNUF.PK, FRE.DE), a German healthcare company, on Monday reaffirmed its annual adjusted earnings growth guidance.For fiscal 2026, exclud...
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius SE & Co. KGaA Slides: Q1 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Fresenius SE & Co. KGaA Earnings release: Q1 2026
Fresenius SE & Co. KGaA released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q1 2026
Fresenius SE & Co. KGaA has published its Q1 2026 quarterly earnings report on May 6, 2026.
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2025
Strong 2025 results featured 7% organic revenue and double-digit core EPS growth, with robust Q4 performance and improved leverage. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, supported by innovation, digitalization, and disciplined capital allocation.
Fresenius SE & Co. KGaA Shareholder letter: Q4 2025
Fresenius SE & Co. KGaA has published a letter to shareholders covering Q4 2025, which was released on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Earnings release: Q4 2025
Fresenius SE & Co. KGaA released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Slides: Q4 2025
Fresenius SE & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Fresenius SE & Co. KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Healthcare trends and portfolio focus have driven growth, with streamlined operations, innovation, and disciplined capital allocation improving margins and returns. Key segments like IV generics, nutrition, MedTech, and biosimilars are positioned for further expansion, while regulatory and market shifts are being navigated through targeted investment and digitalization.